Acomplia – Rimonabant Anti Obesity

Product name: Acomplia
manufacturer: Sanofi-Aventis
Active substance: Rimonabant hydrochloride
Other names: Acomplia; Zimulti
Strength: 20 MG
Quantity: 60 – 750 Tablets

Free worldwide shipping on all orders over $50

  • 30 days easy returns
  • Order yours before 2.30pm for same day dispatch
Guaranteed Safe Checkout


Acomplia – Rimonabant Anti Obesity


Acomplia – Rimonabant anti obesity drug produced and marketed by SanofiAventis. It is an inverse agonist for the cannabinoid receptor CB1. Its main avenue of effect is reduction in appetite. Rimonabant is the first selective CB1 receptor blocker to be approved for use anywhere in the world.

Acomplia – Rimonabant anti obesity drug is an inverse agonist at CB1 receptor that was briefly explored as an anti-obesity treatment but has since been withdrawn due to concerns about inducing depressive states in subjects. In animal models, Acomplia decreases food intake. Rimonabant also inhibits binding of antagonists to δ-opioid receptors in vitro. In retinal pigment epithelial cells, rimonabant prevents oxidative injury in a PI3K/Akt-dependent manner.


as an adjunct to diet and exercise for the treatment of obese patients (BMI ≥30kg per m2), or overweight.

patients (BMI >27kg per m2) with associated risk factor(s) such as type 2 diabetes

or dyslipidaemia.

For use in conjunction with diet and exercise for patients with a body mass index greater than 30 kg/m2, or patients wih a BMI greater than 27 kg/m2 with associated risk factors, such as type 2 diabetes or dyslipidaemia.


The metabolism of (R)-warfarin can be decreased when combined with Acomplia – Rimonabant anti obesity.

(S)-Warfarin The metabolism of (S)-Warfarin can be decreased when combined with Acomplia.

2,5-Dimethoxy-4-ethylamphetamine The risk or severity of Tachycardia can be increased when Rimonabant is combined with 2,5-Dimethoxy-4-ethylamphetamine.

2,5-Dimethoxy-4-ethylthioamphetamine The risk or severity of adverse effects can be increased when Rimonabant is combined with 2,5-Dimethoxy-4-ethylthioamphetamine.

3,4-Methylenedioxyamphetamine The risk or severity of adverse effects can be increased when Rimonabant is combined with 3,4-Methylenedioxyamphetamine.

3,5-diiodothyropropionic acid The metabolism of 3,5-diiodothyropropionic acid can be decreased when combined with Acomplia.

4-Bromo-2,5-dimethoxyamphetamine The risk or severity of adverse effects can be increased when Rimonabant is combined with 4-Bromo-2,5-dimethoxyamphetamine.

4-hydroxycoumarin The metabolism of 4-hydroxycoumarin can be decreased when combined with Acomplia.

4-Methoxyamphetamine The risk or severity of adverse effects can be increased when Rimonabant is combined with 4-Methoxyamphetamine.

5-androstenedione The metabolism of Rimonabant can be decreased when combined with 5-androstenedione.


caution is advised in patients with moderate hepatic impairment; use in patients with severe hepatic impairment is not recommended; there are limited data in patients with moderate renal impairment and rimonabant should not be used in patients with severe renal impairment; should be used with caution in patients over 75 years of age; should be used with caution in patients being treated for epilepsy; should be used with caution in combination with potent CYP3A4 inhibitors; patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucosegalactose malabsorption should not take this medicine; patients should be instructed not to increase their dose of rimonabant; therapy should not be initiated in patients with uncontrolled serious psychiatric illness such as a major depression; use is not recommended in patients taking antidepressant medication; patients who had a cardiovascular event less than six months ago were excluded in studies


The dose is the amount of drug taken at any one time. This can be expressed as the weight of drug (e.g. 250 mg), volume of drug solution (e.g. 10 mL, 2 drops), the number of dosage forms (e.g. 1 capsule, 1 suppository) or some other quantity (e.g. 2 puffs).

The dosage regimen is the frequency at which the drug doses are given. Examples include 2.5 mL twice a day, one tablet three times a day, one injection every four weeks.

The total daily dose is calculated from the dose and the number of times per day the dose is taken.

The dosage form is the physical form of a dose of drug. Common dosage forms include tablets, capsules, creams, ointments, aerosols and patches. Each dosage form may also have a number of specialized forms such as extended-release, buccal, dispersible and chewable tablets. The strength is the amount of drug in the dosage form or a unit of the dosage form (e.g. 500 mg capsule, 250 mg/5 mL suspension).

The route of administration is the way the dosage form is given. Common routes of administration include oral, rectal, inhalation, nasal and topical.

The optimal dosage is the dosage that gives the desired effect with minimum side effects.

There are many factors taken into consideration when deciding a dose of drug – including age of the patient, weight, sex, ethnicity, liver and kidney function and whether the patient smokes. Other medicines may also affect the drug dose.

Dosage instructions are written on the doctor’s prescription or hospital chart, and on the pharmacy label of a prescribed medicine. Dosage instructions are also found on the packaging and inserts of over-the-counter medicines.

Side Effects of Acomplia – Rimonabant Anti Obesity

Data from clinical trials submitted to regulatory authorities showed that Acomplia caused depressive disorders or mood alterations in up to 10% of subjects and suicidal ideation in around 1%, and in Europe it was contraindicated for people with any psychiatric disorder, including depressed or suicidal individuals.[7]

Additionally, nausea and upper respiratory tract infections were very common (occurring in more than 10% of people) adverse effects; common adverse effects (occurring in between 1% and 10% of people) included gastroenteritis, anxiety, irritability, insomnia and other sleep disorders, hot flushes, diarrhea, vomiting, dry or itchy skin, tendonitis, muscle cramps and spasms, fatigue, flu-like symptoms, and increased risk of falling.

The FDA’s advisory committee raised concerns that based on animal data, it appeared that the therapeutic window with regard to CNS toxicity, and specifically seizures was almost nonexistent; the therapeutic dose and the dose that caused seizures in animals appeared to be the same.[2][14][15]

When the EMA reviewed postmarketing surveillance data, it found that the risk of psychiatric disorders in people taking rimonabant was doubled.[2]

Where to Buy Acomplia – Rimonabant Anti Obesity

Buy anti obesity drugs online here at Inter Health Supplies, we offer the best quality pharmaceutics at affordable and current prices, buy rimonabant online, rimonabant online, Inter Health Supplies, best selling anti obesity drugs , Top selling anti obesity drugs. rimonabant , best online offers, top rated anti obesity drugs


There are no reviews yet.

Be the first to review “Acomplia – Rimonabant Anti Obesity”

Your email address will not be published. Required fields are marked *

Acomplia – Rimonabant Anti Obesity
Acomplia – Rimonabant Anti Obesity